Inmune Bio, Inc. (INMB) Stock Price & Analysis
Inmune Bio, Inc. (INMB) fell 1.61% to USD 1.22 as of June 10, 2026 at 07:56 UTC, according to Nexqual real-time market data.
INMB last closed at USD 1.24; the session ranged USD 1.2–1.3 on volume of 256,189 shares. Market capitalization is $32.43M, with a 52-week range of USD 1.09–11.64 (NCM). Source: Nexqual, June 10, 2026 at 07:56 UTC.
Key Statistics (as of June 10, 2026 at 07:56 UTC)
| Price | USD 1.22 |
|---|---|
| Change | ▼ 1.61% (down) |
| Previous Close | USD 1.24 |
| Open | USD 1.26 |
| Day Range | USD 1.2 – 1.3 |
| 52-Week Range | USD 1.09 – 11.64 |
| Volume | 256,189 shares |
| Market Cap | $32.43M |
| Exchange | NCM |
Technical Analysis (INMB)
Nexqual's technical model rates INMB "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:56 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.92 (neutral) |
| vs SMA50 | Below (USD 1.37) |
| MACD | -0.03 (negative) |
Analyst Ratings (INMB)
Wall Street analysts rate INMB "Strong Buy" based on 4 analysts, with a mean price target of USD 7 (range USD 4–9), per Nexqual as of June 10, 2026 at 07:56 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 7 |
| High Target | USD 9 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (INMB)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.2 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.2 vs est -0.18 ▼ miss |
| 2025-12-31 | USD -0.18 vs est -0.27 ▲ beat |
| 2025-09-30 | USD -0.24 vs est -0.33 ▲ beat |
| 2025-06-30 | USD -0.34 vs est -0.38 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:56 UTC.
Financials & Fundamentals (INMB)
| Total Revenue | $0 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -168.78% |
| Debt / Equity | 7.7 |
| Current Ratio | 4.24 |
| Total Cash | $21.36M |
| Total Debt | $1.51M |
| Free Cash Flow | $-11.25M |
Source: Nexqual, June 10, 2026 at 07:56 UTC.
Financial Health Score (INMB)
Nexqual rates Inmune Bio, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 07:56 UTC.
| Growth | Strong — Revenue +257% YoY (annual) |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $21M cash vs $2M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$11M, burning cash |
| Efficiency | Critical — ROE -169%, ROA -52.6% |
Ownership (INMB)
| Insider Ownership | +11.16% |
|---|---|
| Institutional Ownership | +19.70% |
| Shares Outstanding | 26.59M |
| Float | 22.16M |
| Short % of Float | +15.62% |
Source: Nexqual, June 10, 2026 at 07:56 UTC.
Leadership (INMB)
Inmune Bio, Inc. is led by David J. Moss (age 55), President, CEO, Treasurer, Secretary & Director, per Nexqual as of June 10, 2026 at 07:56 UTC.
| President, CEO, Treasurer, Secretary & Director | David J. Moss (age 55) |
|---|---|
| Interim Chief Financial Officer | Cory Randall Ellspermann (age 52) |
| Chief Scientific Officer & Chief Manufacturing Officer | Mark William Lowdell (age 62) |
Major Backers & Investors (INMB)
Notable institutional backers of Inmune Bio, Inc. include Fidelity, AQR Capital Management, LLC, UBS Group AG, according to Nexqual as of June 10, 2026 at 07:56 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.29% |
| AQR Capital Management, LLC | 1.02% |
| UBS Group AG | 0.95% |
| Goldman Sachs | 0.87% |
| Raymond James Financial, Inc. | 0.76% |
| Susquehanna International Group, LLP | 0.73% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.97% |
| Vanguard Group | 5.54% |
| Geode Capital | 1.86% |
| State Street | 1.09% |
Source: Nexqual, June 10, 2026 at 07:56 UTC.
From Inmune Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Terms of the GOSH license include an upfront payment of £250,000 (approximately $0.3 million) which the Company paid during 2025 and a single milestone payment of up to £6,000,000 (approximately $8.1 million at December 31, 2025) due on the first to occur marketing authorization to be granted by the FDA, EMA or MHRA.
- Our mission is to address a broad range of diseases where chronic inflammation and immune dysfunction are primary drivers of pathology.   Lead Program : CORDStrom™ for RDEB Our primary focus is the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) using CORDStrom, our proprietary, pooled, human umbilical cord-derived mesenchymal stromal cell platform.
- The following table summarizes current IP covering our DN-TNF platform technology:     INB-16 / INKmune (Oncology)   INKmune is a replication-incompetent derivative of our proprietary INB-16 cell line.
Partnerships
- All other provisions in the INKmune License Agreement shall continue in full force and effect.   12     University of Pittsburg License Agreement   On October 3, 2017, the Company entered into an Assignment and Assumption Agreement with Immune Ventures related to intellectual property licensed from the University of Pittsburgh.
- During June 2021, the Company entered into the First Amendment to License Agreement with Xencor.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ANVS | Annovis Bio, Inc. | USD 1.77 | ▼ 6.35% |
| ACIU | AC Immune SA | USD 2.26 | ▲ 0.44% |
| ALEC | Alector, Inc. | USD 1.63 | ▼ 0.31% |
| IMRN | Immuron Limited | USD 1.19 | ▼ 4.8% |
| EDSA | Edesa Biotech, Inc. | USD 4.94 | ▼ 9.52% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:56 UTC. This page is informational and not investment advice.